Literature DB >> 8261445

Telomere shortening in renal cell carcinoma.

C Mehle1, B Ljungberg, G Roos.   

Abstract

The ends of human chromosomes consist of a specialized structure, the telomere, composed of repeats of TTAGGG making up a total of 5-15 kilobase pairs, depending on age and proliferative activity of the tissue. The major function of telomeres is to provide stability to chromosomes and protect underlying unique coding sequences from degradation. There is a loss of telomeric sequences following every cell division estimated to be between 50 and 65 basepairs/cell division in human fibroblasts and embryonic kidney cells in vitro. This loss is due to the fact that DNA replication is incomplete for one strand at each telomere end. In lower eukaryotes there is a compensation mechanism provided by the enzyme telomerase, which is inactive in human somatic cells. Telomerase activation has also been detected in vitro immortalized human cells. In this study we analyzed renal cell carcinoma for the occurrence of telomere shortening using the probe (TTAGGG)4. Southern blots of HinfI-digested DNA revealed a shortening of mean telomere restriction fragment (TRF) length of 0.4 to 2.5 kilobase pairs in 2 or 3 intratumoral samples in all 10 tumors analyzed. No obvious intratumoral heterogeneity was found in mean TRF length values. However, heterogeneity was shown by the occurrence of at least two separate peak TRF values in 7 of 10 tumors, indicating the presence of different tumor cell clones. A conflicting observation was made when we evaluated the intensity of the hybridization signals, where three of the tumors showed an increase in hybridization signals despite concomitant TRF reduction. We found no correlation between tumor size and calculated tumor cell divisions undergone. In two tumors, the calculated cell division cycles were unrealistically low compared to the tumor size. These data suggest that telomerase activation might occur in human renal cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8261445

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Telomere analysis by fluorescence in situ hybridization and flow cytometry.

Authors:  M Hultdin; E Grönlund; K Norrback; E Eriksson-Lindström; T Just; G Roos
Journal:  Nucleic Acids Res       Date:  1998-08-15       Impact factor: 16.971

Review 2.  Telomeres in cancer: tumour suppression and genome instability.

Authors:  John Maciejowski; Titia de Lange
Journal:  Nat Rev Mol Cell Biol       Date:  2017-01-18       Impact factor: 94.444

3.  Correlation of clinical features and telomerase activity in human gliomas.

Authors:  F Huang; H Kanno; I Yamamoto; Y Lin; Y Kubota
Journal:  J Neurooncol       Date:  1999-06       Impact factor: 4.130

Review 4.  Applications of telomerase in urologic oncology.

Authors:  J Landman; E Kavaler; M J Droller; B C Liu
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

5.  Telomere elongation observed in immortalized human fibroblasts by treatment with 60Co gamma rays or 4-nitroquinoline 1-oxide.

Authors:  S Sugihara; K Mihara; T Marunouchi; H Inoue; M Namba
Journal:  Hum Genet       Date:  1996-01       Impact factor: 4.132

Review 6.  Structural insights into G-quadruplexes: towards new anticancer drugs.

Authors:  Danzhou Yang; Keika Okamoto
Journal:  Future Med Chem       Date:  2010-04       Impact factor: 3.808

7.  Telomerase activity in human ovarian carcinoma.

Authors:  C M Counter; H W Hirte; S Bacchetti; C B Harley
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

8.  Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays.

Authors:  Meng Chen; Yuanqing Ye; Hushan Yang; Pheroze Tamboli; Surena Matin; Nizar M Tannir; Christopher G Wood; Jian Gu; Xifeng Wu
Journal:  Int J Cancer       Date:  2009-11-15       Impact factor: 7.396

9.  Telomere shortening occurs in subsets of normal breast epithelium as well as in situ and invasive carcinoma.

Authors:  Alan K Meeker; Jessica L Hicks; Edward Gabrielson; William M Strauss; Angelo M De Marzo; Pedram Argani
Journal:  Am J Pathol       Date:  2004-03       Impact factor: 4.307

10.  Heterogeneity in renal cell carcinoma and its impact no prognosis--a flow cytometric study.

Authors:  B Ljungberg; C Mehle; R Stenling; G Roos
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.